ArticleScience translational medicine2016
Local and transient gene expression primes the liver to resist cancer metastasis.
Article in Science translational medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 79 citations in OpenAlex.
- Artificial intelligence in the diagnosis and prognosis of intrahepatic cholangiocarcinoma: Applications and challenges.World journal of gastrointestinal oncology · 2025Review
- Chemokines and their receptors in oral squamous cell carcinoma: mechanisms, clinical significance, and therapeutic implications.Frontiers in immunology · 2025Review
- Nano-enabled strategies for targeted immunotherapy in gastrointestinal cancers.Frontiers in immunology · 2025Review
- Deep learning-assisted diagnosis of liver tumors using non-contrast magnetic resonance imaging: a multicenter study.Frontiers in oncology · 2025Article
- Minimally Invasive Injectable Gel for Local Immunotherapy of Liver and Gastric Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Killing tumor-associated bacteria with a liposomal antibiotic generates neoantigens that induce anti-tumor immune responses.Nature biotechnology · 2024Article
- Lipid-nanoparticle-enabled nucleic acid therapeutics for liver disorders.Acta pharmaceutica Sinica. B · 2024Review
- Nanomedicine-based cancer immunotherapy: a bibliometric analysis of research progress and prospects.Frontiers in immunology · 2024Review
- Nano-Plumber Reshapes Glymphatic-Lymphatic System to Sustain Microenvironment Homeostasis and Improve Long-Term Prognosis after Traumatic Brain Injury.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Reprogramming systemic and local immune function to empower immunotherapy against glioblastoma.Nature communications · 2023Article
- Which patients are prone to suffer liver metastasis? A review of risk factors of metachronous liver metastasis of colorectal cancer.European journal of medical research · 2022Review
- Review
- Government drivers of breast cancer prevention: A spatiotemporal analysis based on the association between breast cancer and macro factors.Frontiers in public health · 2022Article
- Circulating Tumor Cells in Hepatocellular Carcinoma: A Comprehensive Review and Critical Appraisal.International journal of molecular sciences · 2021Review
- Nanoparticle-based approaches to target the lymphatic system for antitumor treatment.Cellular and molecular life sciences : CMLS · 2021Review
- mRNA Delivery of a Bispecific Single-Domain Antibody to Polarize Tumor-Associated Macrophages and Synergize Immunotherapy against Liver Malignancies.Advanced materials (Deerfield Beach, Fla.) · 2021Article
- Macrophage-Mediated Tumor Cell Phagocytosis: Opportunity for Nanomedicine Intervention.Advanced functional materials · 2021Article
- Inorganic Nanomaterial-Mediated Gene Therapy in Combination with Other Antitumor Treatment Modalities.Advanced functional materials · 2021Article
- The role of liver sinusoidal endothelial cells in cancer liver metastasis.American journal of cancer research · 2021Review
- Nano-immunotherapy for each stage of cancer cellular immunity: which, why, and what?Theranostics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
The liver is the primary site of metastasis for gastrointestinal cancers and is a location highly susceptible to the establishment of metastasis in numerous other primary cancers, including breast, lung, and pancreatic cancers. The current standard of care typically consists of primary tumor resection and systemic administration of potent but toxic chemotherapeutics, yielding a minimal improvement in the median survival rate. CXCL12, a chemokine, is a key factor for activating the migration/survival pathways of CXCR4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.